Lack of effect of spironolactone on male genital development.
Spironolactone, which has been shown to have antiandrogen action in mature male rats, was given to pregnant rats from day 14 of pregnancy until delivery in a dose equivalent to the 400-mg adult human regimen. The male members of the resultant litters were then dissected and examined for evidence of pseudohermaphroditism. No evidence of hypospadias, malformation of Wolffian ducts, or narrowing of anogenital distances was found. In the experimental model used, no evidence of an antiandrogen action of spironolactone was found.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D005260:Female; D005333:Fetus / Q000187:drug effects; D005837:Genitalia, Male / Q000002:abnormalities* / Q000187:drug effects / Q000196:embryology; D007021:Hypospadias / Q000139:chemically induced; D008297:Male; D011247:Pregnancy; D051381:Rats; D013148:Spironolactone
D013148:Spironolactone